Takayama M, Miyamoto S, Ikeda A, Mikuni N, Takahashi J B, Usui K, Satow T, Yamamoto J, Matsuhashi M, Matsumoto R, Nagamine T, Shibasaki H, Hashimoto N
Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Neurology. 2004 Aug 10;63(3):510-5. doi: 10.1212/01.wnl.0000133199.65776.18.
To evaluate the usefulness of propofol as an alternative drug to amobarbital for the Wada test.
The authors analyzed 67 right-handed patients out of 123 patients who were candidates for neurosurgical therapy and thus underwent the Wada test as a preoperative evaluation. Twelve were tested with propofol and 55 were tested with amobarbital. Test conditions of the Wada test, recovery time of muscle power to manual muscle testing (MMT) Grade 3 (T3/5) and Grade 5 (T5/5), onset time of the first verbal response (Tverb) after injection and that of the first nonverbal response (Tnon-verb), were compared between the two groups. Power spectrum analysis of EEG background activity during the Wada test was performed and the time and spatial distribution of polymorphic slow activities were also compared in three cases.
With propofol injection, lateralities of language and memory function were identified in 12 and 9 of 12 patients in comparison to amobarbital (52 and 41 of 55 patients detection in language and memory function). No complications with direct intracarotid injection of propofol were observed. T3/5 and T5/5 with propofol injection were shorter while Tverb and Tnon-verb were longer compared to amobarbital. Absolute power of polymorphic slow EEG waves gradually increased and then rapidly decreased with propofol, which was in contrast to amobarbital injection.
With direct intracarotid propofol injection, the Wada test was satisfactorily performed in all 12 patients and 2 more patients with left-handedness or with different injection dose for each side without any complications. Clinical usefulness of propofol as an alternative drug to amobarbital for the Wada test was indicated.
评估丙泊酚作为戊巴比妥用于Wada试验替代药物的有效性。
作者分析了123例神经外科治疗候选患者中的67例右利手患者,这些患者因此接受了Wada试验作为术前评估。12例使用丙泊酚进行测试,55例使用戊巴比妥进行测试。比较了两组Wada试验的测试条件、肌肉力量恢复至徒手肌力测试(MMT)3级(T3/5)和5级(T5/5)的恢复时间、注射后首次言语反应(Tverb)和首次非言语反应(Tnon-verb)的起效时间。对Wada试验期间脑电图背景活动进行了功率谱分析,并对3例患者多形性慢波活动的时间和空间分布进行了比较。
与戊巴比妥相比,丙泊酚注射后,12例患者中有12例和9例分别确定了语言和记忆功能的优势半球(戊巴比妥组55例患者中分别有52例和41例检测到语言和记忆功能优势半球)。未观察到直接颈内动脉注射丙泊酚的并发症。与戊巴比妥相比,丙泊酚注射后的T3/5和T5/5较短,而Tverb和Tnon-verb较长。丙泊酚注射后,多形性慢脑电图波的绝对功率逐渐增加,然后迅速下降,这与戊巴比妥注射相反。
直接颈内动脉注射丙泊酚,所有12例患者及另外2例左利手或两侧注射剂量不同的患者均顺利完成Wada试验,无任何并发症。表明丙泊酚作为戊巴比妥用于Wada试验替代药物具有临床实用性。